A new class of cancer therapies using RNA-guided nucleases for specific cell depletion
Akribion has raised €8.0M across 1 funding round from 6 investors, most recently a Seed round in Feb 2025. Based in Zwingenberg, Germany; active in Healthtech. Data as of 7 Aug 2026.
Timing: in window vs cohort gap · momentum unknown. Funding-only estimates, not predictions and not investment advice — see signals.
| Date | Stage | Amount | Investors | |
|---|---|---|---|---|
| 2025-02-04 | Seed | €8.0M |
| Carma Fund,Bruker Invest,Hessen Kapital I,High-Tech Gründerfonds (HTGF),MP Beteiligungs GmbH,RV Invest |
| View deal → |
